Pfizer Inc PFE

$29.45 +0.09 (0.31%)

Valuation

Market cap
167,347,712,000
Revenue TTM
$62,579,000,000
Net income TTM
$7,771,000,000
P/E (trailing)
9.58
P/E (forward)
9.61
Profit margin
12.42%
Debt to equity
0.70

Trading

Volume
26,027,900
Avg volume
33,363,297
Day's range
$28.95 – $29.50
Shares out
5,699,854,000
Stochastic %K
31%
Beta
0.31
Analysts
Hold
Price target
$30.38

Price

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under...

Show more

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
212 733 2323
Website
https://www.pfizer.com
Address
66 Hudson Boulevard East, New York, United States

Latest news

Stocktwits

Techdamentals Nov 12, 1:51 AM
The S&P 500 rose 1.31% to 7,619.38 on Wednesday, November 11, 2026, and the Nasdaq rose 1.60%, as CoreWeave's results lifted tech stocks. One number from $PFE's latest report: revenue was $16.583 billion in the third quarter of 2026, down 0.4% from $16.654 billion, while research and development spending rose 18% to $3.016 billion. Is it growing, does it make money, can it pay its bills? The Techdamentals IV Calculator reads the fundamentals in plain English, from the company's own reported numbers. See the fundamentals for yourself and sign up for free. Educational, not advice. https://techdamentals.com/v3/PFE?ref=st
0 replies
Shanghi18 Nov 12, 12:55 AM
$PFE Slight PH coil today. For 2maros QQQ give back. $30+ ( I probly take it out for the reset).
0 replies
macrossluvsrobotech Nov 12, 12:16 AM
$LXRX 💊 : AFTER BELL! BLACKSTONE PAYS 1.5BIL! $BX just put $1.5B behind $PFE's injectable berobenatide — proof the obesity race is a trillion-dollar runway. But here's what the headlines gloss over: berobenatide is a jab. Weekly today, monthly ambitions later. It's still a needle. Lexicon's LX9851 is a different category entirely: an ORAL small-molecule GIPR antagonist — a daily pill. No injection, no needle anxiety, no refrigerated pens, no sharps disposal, no injection-site reactions. Just a tablet you take at home. Why this matters: obesity affects 650M+ people. A large share of them refuse injectables entirely — that's a massive under-penetrated market where only orals can compete. $NVO and $LLY both know it; both are racing for oral leadership. And Novo already bought exclusive worldwide rights to LX9851 — up to $1B in milestones — betting real capital on this exact thesis. $PFE's shot may lead on stage and scale. $LXRX's pill leads on access, convenience, and patient preference.
0 replies
macrossluvsrobotech Nov 12, 12:09 AM
$LXRX Blackstone $BX following $NVO 's model, payed 1.5 Bil for Obesity drug from .... $PFE ... https://finance.yahoo.com/healthcare/articles/why-pfizer-believes-leader-glp-150502034.html?guccounter=1 https://www.bloomberg.com/news/articles/2026-11-11/blackstone-puts-up-1-5-billion-for-pfizer-obesity-drug-studies
0 replies
_Crim_Jamer_ Nov 11, 11:01 PM
$PFE Happy Veterans Day everyone.
0 replies
focafoca99 Nov 11, 9:45 PM
$PFE collaborates with Blackstone Life Sciences on a $1.5B co-funding deal for its obesity drug berobenatide. https://www.rapidticker.com/news/pfe-pfizer-and-blackstone-life-sciences-c8fd74
0 replies
dewmoore Nov 11, 8:41 PM
$SLS Big Pharma drops billions on oncology, and the numbers speak for themselves: Gilead ($6B, 2020) paid $6B for Forty Seven& the AML drug FAILED its Phase 3 trials. (That $6B is our BASED... $SLS should be sitting around $30+ per share) Pfizer ($43B, 2023) bought Seagen for $43B ..it FAILED! (A $43B buyout valuation, $SLS hits $200 +per share) Merck (Keytruda) pulls in over $30 billion a year as the ultimate blockbuster oncology kingpin. (At $30B $SLS would sit around $140+ per share) Even better? Out of those 46 survivors, if GPS holds onto 21 of those survivors while the control arm takes the heavy bulk of the deaths, we WIN regardless! 21 GPS survivors easily BEATS the trial's required Hazard Ratio goal of 0.636 as the guy on X points out, the data suggests we won't just beat it—we will SHATTER it + end up with a SICK Hazard Ratio in the 0.1 to 0.3 range! 🚀. Popcorn is ready for earnings and topline data drop TODAY after 4pm !!! $PFE $MRK $JNJ $LLY GLTA!
1 replies
markarchibald Nov 11, 8:27 PM
$PFE StO 1x 12/18 32/CC for.16
0 replies